Literature DB >> 11772131

Pharmacological options for the treatment of Tourette's disorder.

F J Jiménez-Jiménez1, P J García-Ruiz.   

Abstract

Tourette's disorder is a neuropsychiatric disorder characterised clinically by motor and vocal tics, which may be associated to conductual disorders such as obsessive-compulsive disorder (OCD) and attention-deficit hyperactivity disorder (ADHD). Although the neurochemistry of Tourette's disorder is not well known, there are some effective therapies for tics, OCD and ADHD. However, these are not devoid of adverse effects. Tics only require treatment when they interfere with the functioning of the patient. If therapy is needed, monotherapy at the minimal effective dose is desirable, but some patients may require two or more drugs. The most frequently used drugs for tics are antipsychotics (mainly pimozide and haloperidol) and clonidine. The potential usefulness of atypical antipsychotic drugs (risperidone, olanzapine, clozapine, ziprasidone) and other dopaminergic drugs (fluphenazine, sulpiride, tiapride, metoclopramide, piquindone, tetrabenazine), clonazepam, calcium channel antagonists, botulinum toxin, dopamine agonists, selegiline, and other drugs is discussed. The drugs of choice for OCD in patients with Tourette's disorder are the selective serotonin reuptake inhibitors (SSRIs), although the tricyclic antidepressant clomiplamine, which inhibits both serotonin and noradrenaline uptake, has also been found to be useful. ADHD can be treated with some psychostimulants, mainly methylphenidate, although these drugs must be used with caution. Other potentially useful drugs for the treatment of ADHD in patients with Tourette's disorder are clonidine, guanfacine, selegiline, some tricyclic antidepressants, sertraline, pimozide and clonazepam. Finally, the potential value of some nonpharmacological therapies (hypnotherapy, biofeedback, conductual therapies, electroconvulsive therapy, acupuncture and surgery) is briefly reviewed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11772131     DOI: 10.2165/00003495-200161150-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  222 in total

1.  Effective open-label treatment of tourette's disorder with olanzapine.

Authors:  M Stamenkovic; S D Schindler; H N Aschauer; M De Zwaan; U Willinger; E Resinger; S Kasper
Journal:  Int Clin Psychopharmacol       Date:  2000-01       Impact factor: 1.659

2.  Family study and segregation analysis of Tourette syndrome: evidence for a mixed model of inheritance.

Authors:  J T Walkup; M C LaBuda; H S Singer; J Brown; M A Riddle; O Hurko
Journal:  Am J Hum Genet       Date:  1996-09       Impact factor: 11.025

Review 3.  Tourette syndrome. Treatment of tics.

Authors:  R Kurlan
Journal:  Neurol Clin       Date:  1997-05       Impact factor: 3.806

4.  Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.

Authors:  J Jankovic; J Orman
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

5.  A pilot controlled study of fluoxetine for obsessive-compulsive symptoms in children with Tourette's syndrome.

Authors:  R Kurlan; P G Como; C Deeley; M McDermott; M P McDermott
Journal:  Clin Neuropharmacol       Date:  1993-04       Impact factor: 1.592

6.  Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder.

Authors:  F R Sallee; L Nesbitt; C Jackson; L Sine; G Sethuraman
Journal:  Am J Psychiatry       Date:  1997-08       Impact factor: 18.112

7.  Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood.

Authors:  S J Perlmutter; S F Leitman; M A Garvey; S Hamburger; E Feldman; H L Leonard; S E Swedo
Journal:  Lancet       Date:  1999-10-02       Impact factor: 79.321

8.  Fluphenazine and multifocal tic disorders.

Authors:  C G Goetz; C M Tanner; H L Klawans
Journal:  Arch Neurol       Date:  1984-03

9.  Clonidine in Tourette's syndrome.

Authors:  D J Cohen; J G Young; J A Nathanson; B A Shaywitz
Journal:  Lancet       Date:  1979-09-15       Impact factor: 79.321

10.  A four-step hypnotherapy model for Gilles de la Tourette's syndrome.

Authors:  F M Culbertson
Journal:  Am J Clin Hypn       Date:  1989-04
View more
  14 in total

1.  Dopamine receptor modulation of repetitive grooming actions in the rat: potential relevance for Tourette syndrome.

Authors:  Jennifer L Taylor; Abha K Rajbhandari; Kent C Berridge; J Wayne Aldridge
Journal:  Brain Res       Date:  2010-01-28       Impact factor: 3.252

2.  The D1CT-7 mouse model of Tourette syndrome displays sensorimotor gating deficits in response to spatial confinement.

Authors:  Sean C Godar; Laura J Mosher; Hunter J Strathman; Andrea M Gochi; Cori M Jones; Stephen C Fowler; Marco Bortolato
Journal:  Br J Pharmacol       Date:  2015-08-10       Impact factor: 8.739

3.  Tourette syndrome increases risk of bone fractures: a population-based cohort study.

Authors:  Yuan-Yuan Lu; Ming-Yu Wang; I-Hua Wei; Che-Chen Lin; Chih-Chia Huang
Journal:  Eur Child Adolesc Psychiatry       Date:  2016-11-02       Impact factor: 4.785

Review 4.  The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders.

Authors:  Baptiste Pignon; Chloé Tezenas du Montcel; Louise Carton; Antoine Pelissolo
Journal:  Curr Psychiatry Rep       Date:  2017-11-07       Impact factor: 5.285

Review 5.  Fragile X syndrome: A review of clinical management.

Authors:  Reymundo Lozano; Atoosa Azarang; Tanaporn Wilaisakditipakorn; Randi J Hagerman
Journal:  Intractable Rare Dis Res       Date:  2016-08

Review 6.  Animal models of tic disorders: a translational perspective.

Authors:  Sean C Godar; Laura J Mosher; Giuseppe Di Giovanni; Marco Bortolato
Journal:  J Neurosci Methods       Date:  2014-09-20       Impact factor: 2.390

Review 7.  Tic disorders: from pathophysiology to treatment.

Authors:  Liborio Rampello; Alessandro Alvano; Giuseppe Battaglia; Valeria Bruno; Rocco Raffaele; Francesco Nicoletti
Journal:  J Neurol       Date:  2005-12-05       Impact factor: 6.682

Review 8.  Neuropsychiatric consequences of cardiovascular medications.

Authors:  Jeff C Huffman; Theodore A Stern
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

9.  Tetrabenazine in the treatment of Huntington's disease.

Authors:  Diana Paleacu
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

10.  Outpatient Treatment of Tic Disorders Among Children and Adults.

Authors:  Joseph L Smith; Sean Gregory; Nicole McBride; Tanya K Murphy; Eric A Storch
Journal:  Mov Disord Clin Pract       Date:  2017-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.